Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver Ca

Lab values

• (1) Patients who have received non-radical treatment for liver cancer (including external radiotherapy, molecular targeted drugs, immunotherapies, TAI/TAE/TACE treatments, etc.) and whose tumors are still alive, and patients who have experienced tumor recurrence after radical treatment for liver cancer (including surgical resection, ablation therapy) can be included in this study; (2) Portal vein or hepatic vein invasion; (3) Patients with already diagnosed malignant tumors in other parts; (4) Severe diseases of important organs such as heart, lungs, kidneys, and brain; (5) Complications of TACE contraindications: diffuse-type liver cancer or tumor volume accounting for 70% or more of the entire liver, refractory large amounts of ascites, high-flow arteriovenous shunt in the liver; total bilirubin \> 51 umol/L and/or albumin \< 28 g/L, which cannot be improved after symptomatic treatment; combined with active infection, especially inflammation of the biliary system; female patients who are pregnant or breastfeeding; (6) Patients allergic to iodine oil or iodine agents; (7) Patients and/or their families do not agree to participate in the clinical trial.

• (1) The patient's gender is not restricted, and the age is between 18 and 60 years old, with an expected lifespan of ≥ 3 months; (2) Patients diagnosed with primary hepatocellular carcinoma confirmed by histological or cytological examination, or meeting the clinical diagnostic criteria of the "Primary Liver Cancer Diagnosis and Treatment Guidelines" (2024 Edition) issued by the National Health Commission (including chronic liver disease background, typical imaging features, and changes in AFP); (3) CNLC stage Ia and some Ib stage liver cancer (i.e., a single tumor with a diameter of ≤ 5 cm; or 2 to 3 tumors with the maximum diameter of ≤ 3 cm) (those who are not suitable for or unwilling to undergo surgical resection); (4) No vascular invasion of the portal vein, hepatic vein, etc.; (5) Liver function is Child-A grade or can be corrected after liver protection, nutritional fluid therapy, etc.; (6) Eastern Cooperative Oncology Group Status Score (ECOG PS) ≤ 2; (7) After treatment, the following indicators are achieved: white blood cell count ≥ 9.5×109/L and ≤ 3.0×109/L; platelet count ≥ 350×109/L and ≤ 50×109/L; prothrombin time (PT) does not exceed the upper limit of the normal control by 5 seconds; serum creatinine is less than 1.5 times the upper limit of the normal; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are less than 3 times the upper limit of the normal; (8) Clearly inform the patient of the possible advantages and disadvantages before and after the surgery, and the patient and his/her family voluntarily choose the treatment plan and sign the informed consent form.